Contact
searchSearch
HMP Global
Login

Acute Myeloid Leukemia Resource Center

News
Fractionated Gemtuzumab Ozogamicin Results in Improved Survival and MRD Reduction Among Older Patients With AML
02/08/2024
A fractionated schedule of gemtuzumab ozogamicin resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab ozogamicin.
A fractionated schedule of gemtuzumab ozogamicin resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab ozogamicin.
A fractionated schedule of...
02/08/2024
Oncology
From Oncology
Amer Zeidan, MD
Videos
Gaps in the Current Treatment Landscape of Myelodysplastic Syndromes
03/16/2023
Amer Zeidan, MD, discusses gaps in the current treatment options for patients with MDS and the methods he uses to treat this patient population, particularly those who are not eligible for bone marrow transplants and are higher risk.
Amer Zeidan, MD, discusses gaps in the current treatment options for patients with MDS and the methods he uses to treat this patient population, particularly those who are not eligible for bone marrow transplants and are higher risk.
Amer Zeidan, MD, discusses gaps...
03/16/2023
Journal of Clinical Pathways
Andrew Hantel, MD
Videos
Defining Disparities Across Catchment Areas for Comprehensive Cancer Centers in Acute Leukemia
01/05/2023
Andrew Hantel, MD, discusses race-ethnic disparities in acute leukemia research participation, at the 64th Annual ASH Meeting.
Andrew Hantel, MD, discusses race-ethnic disparities in acute leukemia research participation, at the 64th Annual ASH Meeting.
Andrew Hantel, MD, discusses...
01/05/2023
Journal of Clinical Pathways
Jan Bewersdorf, MD
Videos
Cost-Effectiveness of Liposomal vs Conventional Cytarabine-Daunorubicin for AML
01/10/2022
Jan Bewersdorf, MD, discusses study findings suggesting that liposomal cytarabine-daunorubicin may not be a cost-effective for the treatment of older patients with AML under current pricing.
Jan Bewersdorf, MD, discusses study findings suggesting that liposomal cytarabine-daunorubicin may not be a cost-effective for the treatment of older patients with AML under current pricing.
Jan Bewersdorf, MD, discusses...
01/10/2022
Journal of Clinical Pathways
Prapti Patel, MD
Videos
Real-World Efficacy, Safety of First-Line Venetoclax-Based Combination Therapy for AML
01/06/2022
Prapti Patel, MD, discusses outcomes of patients with AML treated with venetoclax-based combination therapy in the real-world setting.
Prapti Patel, MD, discusses outcomes of patients with AML treated with venetoclax-based combination therapy in the real-world setting.
Prapti Patel, MD, discusses...
01/06/2022
Journal of Clinical Pathways
Quiz
Quiz: Integrated Palliative Care Among Patients With AML
05/07/2021
True or False: Integrated palliative and oncology care for patients with acute myeloid leukemia improves quality of life, psychological stress, and end of life care.
True or False: Integrated palliative and oncology care for patients with acute myeloid leukemia improves quality of life, psychological stress, and end of life care.
True or False: Integrated...
05/07/2021
Journal of Clinical Pathways
Quiz
Quiz: Real-World Effectiveness of Enasidenib for Relapsed/Refractory AML
03/03/2021
True or False: First-line enasidenib demonstrates worse efficacy in the real-world setting than in clinical trials for the treatment of relapsed/refractory IDH2-mutated AML.
True or False: First-line enasidenib demonstrates worse efficacy in the real-world setting than in clinical trials for the treatment of relapsed/refractory IDH2-mutated AML.
True or False: First-line...
03/03/2021
Journal of Clinical Pathways
Real-World Treatment Patterns, FLT3 Testing, and Outcomes in AML
Videos
Real-World Treatment Patterns, FLT3 Testing, and Outcomes in AML
01/14/2021
Amer Zeidan, MBBS, MHS, discusses results from a retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in relapsed/refractory AML.
Amer Zeidan, MBBS, MHS, discusses results from a retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in relapsed/refractory AML.
Amer Zeidan, MBBS, MHS,...
01/14/2021
Journal of Clinical Pathways
News
Integrated Palliative and Oncology Care for AML Recommended as New Standard of Care
01/05/2021
Integrated palliative and oncology care for patients with AML improves QoL, psychological stress, and end-of-life care, and researchers recommend it as a new standard of care.
Integrated palliative and oncology care for patients with AML improves QoL, psychological stress, and end-of-life care, and researchers recommend it as a new standard of care.
Integrated palliative and...
01/05/2021
Journal of Clinical Pathways
Real-World Effectiveness of Enasidenib for Relapsed/Refractory AML
Videos
Real-World Effectiveness of Enasidenib for Relapsed/Refractory AML
12/21/2020
Andrew Klink, PhD, MPH, discusses results from a real-world cohort study confirming the effectiveness of enasidenib for relapsed/refractory AML outside the trial setting.
Andrew Klink, PhD, MPH, discusses results from a real-world cohort study confirming the effectiveness of enasidenib for relapsed/refractory AML outside the trial setting.
Andrew Klink, PhD, MPH,...
12/21/2020
Journal of Clinical Pathways
Conference Coverage
Enasidenib Effective for Relapsed/Refractory IDH2-Mutated AML in Real-World Setting
12/06/2020
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Results from a real-world study...
12/06/2020
Journal of Clinical Pathways

Expert Insights

Amer Zeidan, MD
Videos
Gaps in the Current Treatment Landscape of Myelodysplastic Syndromes
03/16/2023
Amer Zeidan, MD, discusses gaps in the current treatment options for patients with MDS and the methods he uses to treat this patient population, particularly those who are not eligible for bone marrow transplants and are higher risk.
Amer Zeidan, MD, discusses gaps in the current treatment options for patients with MDS and the methods he uses to treat this patient population, particularly those who are not eligible for bone marrow transplants and are higher risk.
Amer Zeidan, MD, discusses gaps...
03/16/2023
Journal of Clinical Pathways
Andrew Hantel, MD
Videos
Defining Disparities Across Catchment Areas for Comprehensive Cancer Centers in Acute Leukemia
01/05/2023
Andrew Hantel, MD, discusses race-ethnic disparities in acute leukemia research participation, at the 64th Annual ASH Meeting.
Andrew Hantel, MD, discusses race-ethnic disparities in acute leukemia research participation, at the 64th Annual ASH Meeting.
Andrew Hantel, MD, discusses...
01/05/2023
Journal of Clinical Pathways
Jan Bewersdorf, MD
Videos
Cost-Effectiveness of Liposomal vs Conventional Cytarabine-Daunorubicin for AML
01/10/2022
Jan Bewersdorf, MD, discusses study findings suggesting that liposomal cytarabine-daunorubicin may not be a cost-effective for the treatment of older patients with AML under current pricing.
Jan Bewersdorf, MD, discusses study findings suggesting that liposomal cytarabine-daunorubicin may not be a cost-effective for the treatment of older patients with AML under current pricing.
Jan Bewersdorf, MD, discusses...
01/10/2022
Journal of Clinical Pathways
Prapti Patel, MD
Videos
Real-World Efficacy, Safety of First-Line Venetoclax-Based Combination Therapy for AML
01/06/2022
Prapti Patel, MD, discusses outcomes of patients with AML treated with venetoclax-based combination therapy in the real-world setting.
Prapti Patel, MD, discusses outcomes of patients with AML treated with venetoclax-based combination therapy in the real-world setting.
Prapti Patel, MD, discusses...
01/06/2022
Journal of Clinical Pathways
Real-World Treatment Patterns, FLT3 Testing, and Outcomes in AML
Videos
Real-World Treatment Patterns, FLT3 Testing, and Outcomes in AML
01/14/2021
Amer Zeidan, MBBS, MHS, discusses results from a retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in relapsed/refractory AML.
Amer Zeidan, MBBS, MHS, discusses results from a retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in relapsed/refractory AML.
Amer Zeidan, MBBS, MHS,...
01/14/2021
Journal of Clinical Pathways
Real-World Effectiveness of Enasidenib for Relapsed/Refractory AML
Videos
Real-World Effectiveness of Enasidenib for Relapsed/Refractory AML
12/21/2020
Andrew Klink, PhD, MPH, discusses results from a real-world cohort study confirming the effectiveness of enasidenib for relapsed/refractory AML outside the trial setting.
Andrew Klink, PhD, MPH, discusses results from a real-world cohort study confirming the effectiveness of enasidenib for relapsed/refractory AML outside the trial setting.
Andrew Klink, PhD, MPH,...
12/21/2020
Journal of Clinical Pathways
Interview
Standardized Care and Novel Therapy Development in AML
06/10/2019
JCP Editors
William J. Cardarelli, PharmD, is an experienced pharmacy administrator for more than 20 years, with a large breadth of experience in cost containment and resource allocation in the managed care arena. He has held...
William J. Cardarelli, PharmD, is an experienced pharmacy administrator for more than 20 years, with a large breadth of experience in cost containment and resource allocation in the managed care arena. He has held...
...
06/10/2019
Journal of Clinical Pathways
Sawsan Rashdan, MD
Videos
Future Directions in NSCLC Care: Navigating Pathways, Costs, and Cutting-Edge Therapies
11/14/2024
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate...
11/14/2024
Journal of Clinical Pathways
Videos
Evolving Oncology Pathways, CLL Treatment Advances, and the Role of Multidisciplinary Care Teams
11/12/2024
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD,...
11/12/2024
Journal of Clinical Pathways
Kerry Rogers, MD
Videos
Assessing Fixed-Duration Obinutuzumab, Ibrutinib, and Venetoclax in CLL: A 7-Year Follow-Up
11/08/2024
Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...
Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...
Kerry Rogers, MD, provides a...
11/08/2024
Journal of Clinical Pathways
BDHC Thumbnail
Breaking Down Health Care
Navigating Payer Challenges in Cell and Gene Therapy
11/07/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...
In this Breaking Down Health...
11/07/2024
Cancer Care Business Exchange
Videos
Navigating Multidisciplinary Care: Insights on Oncology Practice Integration and Pharmaceutical Partnerships
11/04/2024
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at...
11/04/2024
Journal of Clinical Pathways
Videos
Custom Pathways in Oncology: Innovations, Stakeholder Collaboration, and Value-Based Care
11/01/2024
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice...
11/01/2024
Journal of Clinical Pathways
Interview
Treatment Options for NSCLC: A Discussion on Coverage, Clinical Outcomes, and Payer Perspectives
10/30/2024
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research...
10/30/2024
Journal of Clinical Pathways
JB
Interview
The Road Ahead for CLL Research and Treatment: Overcoming Challenges and Embracing Innovations in Patient Care
10/25/2024
Learn about recent advancements in CLL treatment including the potential approval of new combination therapies and the evolving landscape of targeted therapies.
Learn about recent advancements in CLL treatment including the potential approval of new combination therapies and the evolving landscape of targeted therapies.
Learn about recent advancements...
10/25/2024
Journal of Clinical Pathways
Jessica Paulus, ScD
Interview
Insights on Lung Cancer Diagnosis Trends and Screening Challenges in Community Oncology
10/23/2024
In this interview, Jessica Paulus, ScD, senior director of real-world research at Ontada, discusses trends in advanced non–small cell and small cell lung cancer diagnoses, the impact of the COVID-19 pandemic on screening, and the need for...
In this interview, Jessica Paulus, ScD, senior director of real-world research at Ontada, discusses trends in advanced non–small cell and small cell lung cancer diagnoses, the impact of the COVID-19 pandemic on screening, and the need for...
In this interview, Jessica...
10/23/2024
Journal of Clinical Pathways
Federico Cappuzzo, MD, National Cancer Institute Regina Elena
Videos
The Impact of Subcutaneous Formulation of Atezolizumab on Treatment for Patients with Non-Small Cell Lung Cancer
10/17/2024
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses...
10/17/2024
Oncology

Newsfeed

News
Fractionated Gemtuzumab Ozogamicin Results in Improved Survival and MRD Reduction Among Older Patients With AML
02/08/2024
A fractionated schedule of gemtuzumab ozogamicin resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab ozogamicin.
A fractionated schedule of gemtuzumab ozogamicin resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab ozogamicin.
A fractionated schedule of...
02/08/2024
Oncology
News
Integrated Palliative and Oncology Care for AML Recommended as New Standard of Care
01/05/2021
Integrated palliative and oncology care for patients with AML improves QoL, psychological stress, and end-of-life care, and researchers recommend it as a new standard of care.
Integrated palliative and oncology care for patients with AML improves QoL, psychological stress, and end-of-life care, and researchers recommend it as a new standard of care.
Integrated palliative and...
01/05/2021
Journal of Clinical Pathways
Conference Coverage
Enasidenib Effective for Relapsed/Refractory IDH2-Mutated AML in Real-World Setting
12/06/2020
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Results from a real-world study...
12/06/2020
Journal of Clinical Pathways
News
Real-World Costs of Azacitidine Treatment in Patients With AML
09/28/2020
09/28/2020
Journal of Clinical Pathways
News
Comparative Effectiveness of 2 Conditioning Regimens for Patients With AML Undergoing Transplantation
07/23/2020
Reduced intensity conditioning (RIC) with fludarabine plus melphalan significantly improves long-term overall survival (OS) and leukemia-free survival (LFS) compared with fludarabine plus busulfan in patients with...
Reduced intensity conditioning (RIC) with fludarabine plus melphalan significantly improves long-term overall survival (OS) and leukemia-free survival (LFS) compared with fludarabine plus busulfan in patients with...
...
07/23/2020
Journal of Clinical Pathways
News
Impact of NGS on Treatment Selection in AML
06/08/2020
Next-generation sequencing (NGS) has the potential to directly impact treatment decisions and outcomes in patients with acute myeloid leukemia (AML), according to a study presented at the American Society of Clinical...
Next-generation sequencing (NGS) has the potential to directly impact treatment decisions and outcomes in patients with acute myeloid leukemia (AML), according to a study presented at the American Society of Clinical...
...
06/08/2020
Journal of Clinical Pathways
News
Long-Term Follow-Up Data Supports Frontline Treatment Option for Older AML Patients
05/21/2020
Venetoclax plus low-dose cytarabine offers a clinically meaningful improvement in survival compared with placebo plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (AML),...
Venetoclax plus low-dose cytarabine offers a clinically meaningful improvement in survival compared with placebo plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (AML),...
...
05/21/2020
Journal of Clinical Pathways
News
Integrated Palliative, Oncology Care for AML Improves PROs
05/15/2020
A study to be presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program (May 29-31, 2020) highlights the results of an integrated palliative and oncology care model for patients...
A study to be presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program (May 29-31, 2020) highlights the results of an integrated palliative and oncology care model for patients...
A...
05/15/2020
Journal of Clinical Pathways
News
Enhancing Survival in Endometrial Cancer: Impact of Immunotherapy and Chemotherapy Combination Therapy
11/13/2024
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with...
11/13/2024
Journal of Clinical Pathways
News
Under 50% of Oncology Practices Offer Survivorship Clinics
11/12/2024
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice...
11/12/2024
Journal of Clinical Pathways
Videos
Evolving Oncology Pathways, CLL Treatment Advances, and the Role of Multidisciplinary Care Teams
11/12/2024
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD,...
11/12/2024
Journal of Clinical Pathways
News
Experts Reach Consensus on Myelofibrosis Management, Offering New Hope for Patients
11/08/2024
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international...
11/08/2024
Journal of Clinical Pathways
Conference Coverage
Oncology Pathways Research: Challenges, Adoption, and Future Trends
11/08/2024
In an exclusive interview with the Journal of Clinical Pathways, Cindy Chen, Head of Research at HMP Market Access Insights, shares insights into the challenges, adoption, and future trends of oncology pathways research. Her discussion draws...
In an exclusive interview with the Journal of Clinical Pathways, Cindy Chen, Head of Research at HMP Market Access Insights, shares insights into the challenges, adoption, and future trends of oncology pathways research. Her discussion draws...
In an exclusive interview with...
11/08/2024
Journal of Clinical Pathways
News
Advancing Personalized Treatment in Endometrial Cancer With the HECTOR Deep Learning Model
11/06/2024
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published...
11/06/2024
Journal of Clinical Pathways
Videos
Navigating Multidisciplinary Care: Insights on Oncology Practice Integration and Pharmaceutical Partnerships
11/04/2024
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at...
11/04/2024
Journal of Clinical Pathways
Videos
Custom Pathways in Oncology: Innovations, Stakeholder Collaboration, and Value-Based Care
11/01/2024
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice...
11/01/2024
Journal of Clinical Pathways
News
Influence of Socioeconomic and Demographic Factors on Myelofibrosis Outcomes
10/30/2024
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic...
10/30/2024
Journal of Clinical Pathways
News
Hypertension and Endometrial Cancer Risk: A Systematic Review and Meta-Analysis
10/25/2024
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and...
10/25/2024
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Integrated Palliative Care Among Patients With AML
05/07/2021
True or False: Integrated palliative and oncology care for patients with acute myeloid leukemia improves quality of life, psychological stress, and end of life care.
True or False: Integrated palliative and oncology care for patients with acute myeloid leukemia improves quality of life, psychological stress, and end of life care.
True or False: Integrated...
05/07/2021
Journal of Clinical Pathways
Quiz
Quiz: Real-World Effectiveness of Enasidenib for Relapsed/Refractory AML
03/03/2021
True or False: First-line enasidenib demonstrates worse efficacy in the real-world setting than in clinical trials for the treatment of relapsed/refractory IDH2-mutated AML.
True or False: First-line enasidenib demonstrates worse efficacy in the real-world setting than in clinical trials for the treatment of relapsed/refractory IDH2-mutated AML.
True or False: First-line...
03/03/2021
Journal of Clinical Pathways
Quiz
Quiz: Treatment vs Supportive Care for AML in Real-World Setting
11/20/2020
11/20/2020
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

News
Fractionated Gemtuzumab Ozogamicin Results in Improved Survival and MRD Reduction Among Older Patients With AML
02/08/2024
A fractionated schedule of gemtuzumab ozogamicin resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab ozogamicin.
A fractionated schedule of gemtuzumab ozogamicin resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab ozogamicin.
A fractionated schedule of...
02/08/2024
Oncology
Amer Zeidan, MD
Videos
Gaps in the Current Treatment Landscape of Myelodysplastic Syndromes
03/16/2023
Amer Zeidan, MD, discusses gaps in the current treatment options for patients with MDS and the methods he uses to treat this patient population, particularly those who are not eligible for bone marrow transplants and are higher risk.
Amer Zeidan, MD, discusses gaps in the current treatment options for patients with MDS and the methods he uses to treat this patient population, particularly those who are not eligible for bone marrow transplants and are higher risk.
Amer Zeidan, MD, discusses gaps...
03/16/2023
Journal of Clinical Pathways
Andrew Hantel, MD
Videos
Defining Disparities Across Catchment Areas for Comprehensive Cancer Centers in Acute Leukemia
01/05/2023
Andrew Hantel, MD, discusses race-ethnic disparities in acute leukemia research participation, at the 64th Annual ASH Meeting.
Andrew Hantel, MD, discusses race-ethnic disparities in acute leukemia research participation, at the 64th Annual ASH Meeting.
Andrew Hantel, MD, discusses...
01/05/2023
Journal of Clinical Pathways
Jan Bewersdorf, MD
Videos
Cost-Effectiveness of Liposomal vs Conventional Cytarabine-Daunorubicin for AML
01/10/2022
Jan Bewersdorf, MD, discusses study findings suggesting that liposomal cytarabine-daunorubicin may not be a cost-effective for the treatment of older patients with AML under current pricing.
Jan Bewersdorf, MD, discusses study findings suggesting that liposomal cytarabine-daunorubicin may not be a cost-effective for the treatment of older patients with AML under current pricing.
Jan Bewersdorf, MD, discusses...
01/10/2022
Journal of Clinical Pathways
Prapti Patel, MD
Videos
Real-World Efficacy, Safety of First-Line Venetoclax-Based Combination Therapy for AML
01/06/2022
Prapti Patel, MD, discusses outcomes of patients with AML treated with venetoclax-based combination therapy in the real-world setting.
Prapti Patel, MD, discusses outcomes of patients with AML treated with venetoclax-based combination therapy in the real-world setting.
Prapti Patel, MD, discusses...
01/06/2022
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use